Chester County News and Community Website
WILMINGTON, DE — AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise for its fixed-dose triple-combination therapy, BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or …
AstraZeneca Reports Promising Phase III Trial Results for BREZTRI AEROSPHERE Read More WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly statistically significant and clinically meaningful improvement in …
DESTINY-Breast09 Trial Demonstrates Promising Results for ENHERTU in Combination with Pertuzumab Read More WILMINGTON, DE — High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, significantly improves progression-free survival (PFS) compared to the current 1st-line …
ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer Trial Read More WILMINGTON, DE — New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers significant reductions in LDL cholesterol (LDL-C) when combined with standard-of-care statin …
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial Read More WILMINGTON, DE — AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer (MIBC), making it the first perioperative immunotherapy available in the U.S. …
FDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder Cancer Read More WILMINGTON, DE — AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma exacerbations. The trial demonstrated …
AstraZeneca’s AIRSUPRA Proven Effective in Reducing Severe Asthma Attacks Read More